⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367522 | 0.67 | — | — | |
| SCHEMBL600513 | 0.60 | ALDH1A1 (0.32) | — | |
| SCHEMBL14249193 | 0.53 | — | — | |
| SCHEMBL4065362 | 0.53 | — | — | |
| SCHEMBL13407 | 0.51 | — | — | |
| Methane SCHEMBL222390 | 0.48 | — | — | |
| SCHEMBL2221687 | 0.48 | — | — | |
| Methane SCHEMBL190374 | 0.48 | — | — | |
| SCHEMBL3754347 | 0.47 | — | — | |
| SCHEMBL4328507 | 0.47 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3994138-A1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRalpha) MODULATORS | Lead Pharma Holding B.V. (NL) | 2022-05-11 | — | — | EP | claimed |
| WO-2021001453-A1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS | LEAD PHARMA HOLDING B.V. (NL) | 2021-01-07 | — | — | WO | claimed |
| US-20110318345-A1 | NASAL DELIVERY | OPTINOSE AS (NO) | 2011-12-29 | — | — | US | claimed |
| WO-2010029441-A2 | NASAL DELIVERY | OPTINOSE AS (NO) | 2010-03-18 | — | — | WO | claimed |
| US-12409171-B2 | Pharmaceutically active pyrazolo-pyridone modulators of DCN1/2-mediated cullin neddylation | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2025-09-09 | — | — | US | disclosed |
| EP-3994138-B1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRALPHA) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2025-04-02 | — | — | EP | disclosed |
| EP-4045503-B1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERR-ALPHA) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2023-12-06 | — | — | EP | disclosed |
| CN-113149897-B | 2, 6-substituted-4-oxyterpene phenolic pyridine compound and preparation method and application thereof | 福建省中科生物股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230248925-A1 | NASAL DELIVERY DEVICES | Optinose, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-11602603-B2 | Nasal delivery devices | Optinose, Inc. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-4126225-A1 | SMALL MOLECULES INDUCING THE DEGRADATION OF THE CELLULAR PRION PROTEIN | Istituto Nazionale di Fisica Nucleare (IT) | 2023-02-08 | — | — | EP | disclosed |
| US-20220280488-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-PYRIDONE MODULATORS OF DCN1/2-MEDIATED CULLIN NEDDYLATION | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-09-08 | — | — | US | disclosed |
| EP-1641454-A1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641455-A1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005016245-A2 | COMPOUNDS HAVING INHIBITIVE ACTIVITY OF PHOSPHATIDYLINOSITOL 3-KINASE AND METHODS OF USE THEREOF | ZENTARIS GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
| US-20050026946-A1 | GSK-3 inhibitors | PFIZER INC | 2005-02-03 | — | — | US | disclosed |
| WO-2005000304-A1 | PYRAZOLO[3,4-B]PYRIDIN-6-ONES AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000303-A1 | PYRAZOLO`3,4-B!PYRIDIN-6-ONES AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266815-A1 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
| US-20040266815-A1 | Pyrazolo[3,4-b]pyridin-6-ones as GSK-3 inhibitors | PFIZER INC | 2004-12-30 | — | — | US | disclosed |